At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Trading 01-12 11:49:20 EST
324.50
-1.60
-0.49%
High328.47Low322.74Vol889.50K
Open328.00D1 Closing326.10Amplitude1.76%
Mkt Cap174.74BTradable Cap174.25BTotal Shares538.48M
T/O289.14MT/O Rate0.17%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Spyre Therapeutics Appoints Kate Tansey Chevlen as Chief Commercial Officer
Reuters  ·  01-12 21:01
Spyre Therapeutics Appoints Kate Tansey Chevlen as Chief Commercial Officer
How Amgen’s DISCO Oncology Licensing Deal Will Impact Amgen (AMGN) Investors
Simply Wall St.  ·  01-11 18:16
How Amgen’s DISCO Oncology Licensing Deal Will Impact Amgen (AMGN) Investors
Amgen Inc. Stock Underperforms Friday When Compared To Competitors
Dow Jones  ·  01-10 05:35
Amgen Inc. Stock Underperforms Friday When Compared To Competitors
Goldman Sachs Adjusts Price Target on Amgen to $403 From $400, Maintains Buy Rating
MT Newswires Live  ·  01-09
Goldman Sachs Adjusts Price Target on Amgen to $403 From $400, Maintains Buy Rating
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan
TIPRANKS  ·  01-09
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan
Amgen Inc : Truist Securities Raises Target Price to $319 From $318
THOMSON REUTERS  ·  01-08
Amgen Inc : Truist Securities Raises Target Price to $319 From $318
Call for Application for 2026 Tsinghua Amgen Scholars Program
prnewswire  ·  01-08
Call for Application for 2026 Tsinghua Amgen Scholars Program
Amgen Shares Rise After Upgrade From UBS
MT Newswires Live  ·  01-08
Amgen Shares Rise After Upgrade From UBS
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
Benzinga  ·  01-08
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up 5%; Eli Lilly Rises 4% to Record High; Amgen up 3%; Roche, Novo up Around 2%
Tiger Newspress  ·  01-07
Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up 5%; Eli Lilly Rises 4% to Record High; Amgen up 3%; Roche, Novo up Around 2%
UBS Upgrades Amgen to Buy From Neutral, Raises Price Target to $380 From $317
MT Newswires Live  ·  01-07
UBS Upgrades Amgen to Buy From Neutral, Raises Price Target to $380 From $317
Amgen Coverage Assumed by UBS at Buy vs Previous Rating of Neutral
Dow Jones  ·  01-07
Amgen Coverage Assumed by UBS at Buy vs Previous Rating of Neutral
Disco Pharmaceuticals: Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies With Amgen
THOMSON REUTERS  ·  01-07
Disco Pharmaceuticals: Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies With Amgen
Disco Pharmaceuticals: Disco Will Be Eligible to Receive up to $618 Mln Total Potential Deal Value Plus Royalties
THOMSON REUTERS  ·  01-07
Disco Pharmaceuticals: Disco Will Be Eligible to Receive up to $618 Mln Total Potential Deal Value Plus Royalties
UBS Raises Amgen (AMGN.US) Target to $380: Two Pipeline Drugs Expected to Drive Growth Through 2030
Stock News  ·  01-07
UBS Raises Amgen (AMGN.US) Target to $380: Two Pipeline Drugs Expected to Drive Growth Through 2030
PRESS DIGEST- Financial Times - January 7
Reuters  ·  01-07
PRESS DIGEST- Financial Times - January 7
Weight-Loss Drugmakers' Stocks Jump. Arrowhead up over 17%; Structure Therapeutics up over 6%; Novo Nordisk up 5%; Viking, Pfizer, Eli Lilly up Around 2%
Tiger Newspress  ·  01-06
Weight-Loss Drugmakers' Stocks Jump. Arrowhead up over 17%; Structure Therapeutics up over 6%; Novo Nordisk up 5%; Viking, Pfizer, Eli Lilly up Around 2%
BRIEF-Amgen Acquires Dark Blue Therapeutics For Up To $840 Million
Reuters  ·  01-06
BRIEF-Amgen Acquires Dark Blue Therapeutics For Up To $840 Million
Dark Blue Therapeutics Acquired by Amgen for up to $840 Million
THOMSON REUTERS  ·  01-06
Dark Blue Therapeutics Acquired by Amgen for up to $840 Million
Amgen acquires Dark Blue Therapeutics to boost oncology research
Reuters  ·  01-06
Amgen acquires Dark Blue Therapeutics to boost oncology research

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--